Roche Holding AG said its MabThera drug, when used with standard chemotherapy, almost doubles the time for the slow form of non-Hodgkin's lymphoma to worsen compared with chemotherapy alone. Roche said the drug may provide hope for a "durable remission" for some patients, and the firm plans to seek regulatory approval for the new use in early 2004.

Full Story:

Related Summaries